Florian Gnad

Florian Gnad

Auto-generated profile, based on publicly available information

Florian Gnad

Department of Bioinformatics and Computational Biology, Genentech Inc, South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2009 in Science
Verified
Journal Article
Closed access
PDF file
CCChunaram Choudhary
Chunaram Choudhary
CKChanchal Kumar
Chanchal Kumar
FGFlorian Gnad
Florian Gnad
MNMichael L. Nielsen
Michael L. Nielsen
MRMichael Rehman
Michael Rehman
MMMatthias Mann
Matthias Mann
Lysine Acetylation Catalog: Covalent posttranslational modification is an essential cellular regulatory mechanism by which the activity of proteins can be controlled. Advances in mass spectrometry made it possible for Choudhary et al. (p. 834 , published online 16 July) to assess the prevalence of lysine acetylation throughout the whole proteome. Acetylation is much more widespread than previously appreciated and occurs on proteins participating in all sorts of biological functions. Acetylation can influence susceptibility of proteins to phosphorylation and occurs frequently on enzymes that control the modification of other proteins by covalent ubiquitination and on proteins that form large macromolecular complexes. The findings also help to characterize the actions of lysine deacetylase inhibitors, which have shown clinical promise in treatments for cancer.

1 November 2006 in Cell
Verified
Journal Article
Closed access
JOJesper V. Olsen
Jesper V. Olsen
BBBlagoy Blagoev
Blagoy Blagoev
FGFlorian Gnad
Florian Gnad
BMBoris Macek
Boris Macek
CKChanchal Kumar
Chanchal Kumar
MMMatthias Mann
Matthias Mann

12 January 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
JOJesper V. Olsen
Jesper V. Olsen
MVMichiel Vermeulen
Michiel Vermeulen
ASAnna Santamaria
Anna Santamaria
CKChanchal Kumar
Chanchal Kumar
MMMartin L. Miller
Martin L. Miller
MMMatthias Mann
Matthias Mann
Protein phosphorylation during the cell cycle may be an all-or-none process in many instances.

2 September 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CRCharles M Rudin
Charles M Rudin
SDSteffen Durinck
Steffen Durinck
ESEric W Stawiski
Eric W Stawiski
JPJohn T. Poirier
John T. Poirier
ZMZora Modrusan
Zora Modrusan
SSSomasekar Seshagiri
Somasekar Seshagiri
Sekar Seshagiri and colleagues report exome, transcriptome and copy-number alteration data in small-cell lung cancer. The authors find SOX2 amplification in 27% of samples and also identify a recurrent RFL-MYCL1 fusion. Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis. Here, we obtained exome, transcriptome and copy-number alteration data from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLC and lymphoblastoid cell lines. We also obtained data for 4 primary tumors and 23 SCLC cell lines. We identified 22 significantly mutated genes in SCLC, including genes encoding kinases, G protein–coupled receptors and chromatin-modifying proteins. We found that several members of the SOX family of genes were mutated in SCLC. We also found SOX2 amplification in ∼27% of the samples. Suppression of SOX2 using shRNAs blocked proliferation of SOX2-amplified SCLC lines. RNA sequencing identified multiple fusion transcripts and a recurrent RLF-MYCL1 fusion. Silencing of MYCL1 in SCLC cell lines that had the RLF-MYCL1 fusion decreased cell proliferation. These data provide an in-depth view of the spectrum of genomic alterations in SCLC and identify several potential targets for therapeutic intervention.

15 August 2012 in Nature
Verified
Journal Article
Open access
PDF file
SSSomasekar Seshagiri
Somasekar Seshagiri
ESEric W. Stawiski
Eric W. Stawiski
SDSteffen Durinck
Steffen Durinck
ZMZora Modrusan
Zora Modrusan
ESElaine E. Storm
Elaine E. Storm
FSFrederic J. de Sauvage
Frederic J. de Sauvage
Exomes, transcriptomes and copy-number alterations in a sample of more than 70 primary human colonic tumours were analysed in an attempt to characterize the genomic landscape; in addition to finding alterations in genes associated with commonly mutated signalling pathways, recurrent gene fusions involving R-spondin family members were also found to occur in approximately 10% of colonic tumours, revealing a potential new therapeutic target. An analysis of exomes, transcriptomes and copy-number alterations in more than 70 primary human colon tumours and matched normal controls has identified more than 35,000 protein-altering somatic mutations, most of which have been validated. In addition to alterations in genes involved in the Wnt pathway, chromatin remodelling and receptor-tyrosine-kinase signalling, the authors identify recurrent gene fusions involving R-spondin family members that collectively occur in 10% of colon tumors; as such they may provide a potential therapeutic target. There is evidence to suggest that these fusions may have a role in the activation of Wnt signalling and tumorigenesis. Identifying and understanding changes in cancer genomes is essential for the development of targeted therapeutics1. Here we analyse systematically more than 70 pairs of primary human colon tumours by applying next-generation sequencing to characterize their exomes, transcriptomes and copy-number alterations. We have identified 36,303 protein-altering somatic changes that include several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3. Our analysis for significantly mutated cancer genes identified 23 candidates, including the cell cycle checkpoint kinase ATM. Copy-number and RNA-seq data analysis identified amplifications and corresponding overexpression of IGF2 in a subset of colon tumours. Furthermore, using RNA-seq data we identified multiple fusion transcripts including recurrent gene fusions involving R-spondin family members RSPO2 and RSPO3 that together occur in 10% of colon tumours. The RSPO fusions were mutually exclusive with APC mutations, indicating that they probably have a role in the activation of Wnt signalling and tumorigenesis. Consistent with this we show that the RSPO fusion proteins were capable of potentiating Wnt signalling. The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer.

29 February 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RBRaphael Bueno
Raphael Bueno
ESEric W Stawiski
Eric W Stawiski
LGLeonard D Goldstein
Leonard D Goldstein
SDSteffen Durinck
Steffen Durinck
ARAssunta De Rienzo
Assunta De Rienzo
SSSomasekar Seshagiri
Somasekar Seshagiri